RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA

BACKGROUND: The outcome for glioblastoma (GBM) remains dismal with a median survival of 15 months. Vascular endothelial growth factor (VEGF) is a highly upregulated proangiogenic growth factor in GBM that contributes to tumor-associated immunosuppression by inhibition of dendritic cell maturation an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Ahluwalia, Manmeet, Peereboom, David, Schilero, Cathy, Forst, Deborah, Wong, Eric, Wen, Patrick, Reardon, David
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217628/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.971
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars